Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resmetirom and Atorvastatin Interaction Study
NCT02749578Phase 1Completed
- Sponsor
- Madrigal Pharmaceuticals
- Start
- Apr 2016
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of resmetirom in Nonalcoholic steatohepatitis (NASH), sponsored by Madrigal Pharmaceuticals. Primary endpoint: Area under the curve from the time of dosing extrapolated to infinity at 72 hours. Started Apr 2016; status: completed.
02
Drugs
resmetirom
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT02749578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02749578.